PDF(Pubmed)
Abstract：
UNASSIGNED: Post-COVID-19 syndrome, or Long Covid (LC) refers to symptoms persisting 12 weeks after the COVID-19 infection. LC comprises a wide range of dysautonomia symptoms, including fatigue, breathlessness, palpitations, dizziness, pain and brain fog. This study tested the feasibility and estimated the efficacy, of a Heart Rate Variability Biofeedback (HRV-B) programme via a standardised slow diaphragmatic breathing technique in individuals with LC.
UNASSIGNED: LC patients underwent a 4-week HRV-B intervention for 10 minutes twice daily for 4 weeks using the Polar H10 ECG (Electrocardiogram) chest strap and Elite HRV phone application. Outcome measures C19-YRSm (Yorkshire Rehabilitation Scale modified), Composite Autonomic Symptom Score (COMPASS-31), WHO Disability Assessment Schedule (WHODAS), EQ5D-5L (EuroQol 5 Dimensions) and Root Mean Square of Successive Differences between heartbeats (RMSSD) using a Fitbit device were recorded before and after the intervention. The study was pre-registered at clinicaltrials.gov NCT05228665.
UNASSIGNED: A total of 13 participants (54% female, 46% male) completed the study with high levels of independent use of technology, data completeness and intervention adherence. There was a statistically significant improvement in C19YRS-m (P = .001), COMPASS-31 (P = .007), RMSSD (P = .047), WHODAS (P = .02) and EQ5D Global Health Score (P = .009). Qualitative feedback suggested participants could use it independently, were satisfied with the intervention and reported beneficial effects from the intervention.
UNASSIGNED: HRV-B using diaphragmatic breathing is a feasible intervention for LC. The small sample size limits generalisability. HRV-B in LC warrants further exploration in a larger randomised controlled study.
UNASSIGNED: LC patients underwent a 4-week HRV-B intervention for 10 minutes twice daily for 4 weeks using the Polar H10 ECG (Electrocardiogram) chest strap and Elite HRV phone application. Outcome measures C19-YRSm (Yorkshire Rehabilitation Scale modified), Composite Autonomic Symptom Score (COMPASS-31), WHO Disability Assessment Schedule (WHODAS), EQ5D-5L (EuroQol 5 Dimensions) and Root Mean Square of Successive Differences between heartbeats (RMSSD) using a Fitbit device were recorded before and after the intervention. The study was pre-registered at clinicaltrials.gov NCT05228665.
UNASSIGNED: A total of 13 participants (54% female, 46% male) completed the study with high levels of independent use of technology, data completeness and intervention adherence. There was a statistically significant improvement in C19YRS-m (P = .001), COMPASS-31 (P = .007), RMSSD (P = .047), WHODAS (P = .02) and EQ5D Global Health Score (P = .009). Qualitative feedback suggested participants could use it independently, were satisfied with the intervention and reported beneficial effects from the intervention.
UNASSIGNED: HRV-B using diaphragmatic breathing is a feasible intervention for LC. The small sample size limits generalisability. HRV-B in LC warrants further exploration in a larger randomised controlled study.
摘要：
■COVID-19后综合征，或长Covid(LC)是指COVID-19感染后持续12周的症状。LC包括广泛的自主神经障碍症状，包括疲劳,呼吸困难,心悸,头晕,疼痛和脑雾。这项研究测试了可行性并估计了疗效，通过标准化的缓慢膈呼吸技术在LC患者中进行心率变异性生物反馈（HRV-B）程序。
■LC患者使用PolarH10ECG（心电图）胸带和EliteHRV电话应用，每天两次，持续4周，接受4周HRV-B干预，持续10分钟。结果指标C19-YRSm（约克郡康复量表修改），综合自主症状评分（COMPASS-31），世卫组织残疾评估时间表(WHODAS)在干预前后记录EQ5D-5L(EuroQol5维)和使用Fitbit设备的心跳之间的连续差异的均方根(RMSSD)。该研究已在clinicaltrials.govNCT05228665上预先注册。
■共有13名参与者（54%为女性，46％的男性）以高水平的独立使用技术完成了研究，数据的完整性和干预依从性。C19YRS-m有统计学上的显着改善（P=.001），COMPASS-31（P=.007），RMSSD（P=.047），WHODAS（P=.02）和EQ5D全球健康评分（P=.009）。定性反馈建议参与者可以独立使用它，对干预措施感到满意，并报告了干预措施的有益效果。
■使用膈呼吸的HRV-B是LC的可行干预措施。小样本量限制了泛化性。LC中的HRV-B值得在更大的随机对照研究中进一步探索。
■LC患者使用PolarH10ECG（心电图）胸带和EliteHRV电话应用，每天两次，持续4周，接受4周HRV-B干预，持续10分钟。结果指标C19-YRSm（约克郡康复量表修改），综合自主症状评分（COMPASS-31），世卫组织残疾评估时间表(WHODAS)在干预前后记录EQ5D-5L(EuroQol5维)和使用Fitbit设备的心跳之间的连续差异的均方根(RMSSD)。该研究已在clinicaltrials.govNCT05228665上预先注册。
■共有13名参与者（54%为女性，46％的男性）以高水平的独立使用技术完成了研究，数据的完整性和干预依从性。C19YRS-m有统计学上的显着改善（P=.001），COMPASS-31（P=.007），RMSSD（P=.047），WHODAS（P=.02）和EQ5D全球健康评分（P=.009）。定性反馈建议参与者可以独立使用它，对干预措施感到满意，并报告了干预措施的有益效果。
■使用膈呼吸的HRV-B是LC的可行干预措施。小样本量限制了泛化性。LC中的HRV-B值得在更大的随机对照研究中进一步探索。
